Rapid Micro Biosystems : Corporate Presentation — May 2026

Published: 2026-05-13 17:01:08 ET RPID

Published on 05/13/2026 at 05:01 pm EDT

May 2026

R A P I D M I C R O B I O S Y S T E M S

N A S D A Q : R P I D

trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.

Rapid Micro Biosystems

We are transforming a critical, regulated part of the global pharmaceutical manufacturing process, bringing microbial quality control into

the 21st century.

Rapid Micro Biosystems

Rapid Micro Biosystems © 2026, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc. 3

2 0 2 5 R E V E N U E

G L O B AL S Y S T E M S (1)

C U S T O M ER S

Rapid Micro Biosystems

$33.6M

Total Revenue

190

Cumulative Placements

75%

Top 20 Global Pharma (2)

20%

Year / Year Growth

$17.8M

Recurring Revenue

155

Cumulative Validations

~20

Countries

86%

Approved CAR-T Manufacturers

Rapid Micro Biosystems

© 2026, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.

As of December 31, 2025 4

By revenue

Strong Q1 2026 results reinforce consistent long-term execution

S E L E C T Q 1 2 0 2 6 H I G H L I G H T S

Exceeded Q1 revenue, system placement and validation guidance; 14th consecutive quarter of meeting / exceeding revenue guidance

Product revenue growth of 36%, with 30%+ consumable revenue growth vs. Q1 2025

Recurring revenue grew 28% vs. Q1 2025; constituted 63% of total revenue

Meaningful product gross margin expansion with 15-percentage point increase vs. Q1 2025

Following receipt of largest-ever system order from Amgen in Q4 2025, received multi-system follow-on order from Samsung Biologics to expand their Growth Direct deployment

Advanced strategic partnership with MilliporeSigma to drive growth, margin expansion and innovation including execution of Services Agreement

Announced anticipated H2 2026 release of next-generation cloud native software that is expected to deliver additional value to Growth Direct customers through AI-driven analytics and insights

Q 1 2 0 2 6

Gross Margin

Mid-single

digit %

Balance Sheet

Cash & Investments

Outstanding Debt

$23M

$20M

Remaining Debt

Facility Capacity

$25M

RE SU LT S 1

AC T U A L 1

G U I D AN C E 2

P&L and KPIs

Total Revenue

$8.0M

$7.5M+

Recurring Revenue

$5.1M

Systems Placed

At least 5

Systems Validated

At least 3

Rapid Micro Biosystems

Preliminary and unaudited for the first quarter ended / as of March 31, 2026 5

Guidance issued March 12, 2026

Microbial quality control (MQC) has not kept up with pharma industry innovation

F A C T O R S D R I V I N G C H A N G E

Scientific and +

technology innovation

Growing demand for

more complex therapies

Faster & leaner

manufacturing

Data integrity &

security focus

Regulatory

scrutiny

T O D A Y

Discovery & research

High-throughput R&D automation

Quality control (QC) & Analysis

Bioprocessing & manufacturing

Flexible single use technologies

Challenges in a traditional MQC lab

Manual, paper-based and slow

Subjective and prone to human error

Insecure and lacking data integrity

High volume testing and mandated by regulators

Modernizing MQC with the Growth Direct® platform

The only fully automated,

high-throughput and secure MQC solution…

…designed to deliver a compelling value proposition

Proprietary

Consumables

Data

Integrity

Supports global quality regulatory compliance

and improved data handling and management

Data &

Software

Operational

Efficiency

Enables faster decision making by accelerating

time to results by 50% or faster compared to the traditional method

Insight &

Accuracy

Global Validation &

Support Services

Substantially reduce human quality control

errors and the risk of costly recalls and regulatory interventions

THE GROWTH DIRECT® (GD) PLATFORM

Growth Direct® automates all MQC tests in pharma manufacturing

The only fully automated non-destructive growth-based

technology impacting mission-critical microbial QC testing applications

For Environmental Monitoring

Tryptic Soy Agar (TSA) with Lecithin

TSA with LP80HT (histidine and thiosulphate)

For Water Testing

R2 Agar (R2A)

For Bioburden Testing

Sabouraud Dextrose Agar (SDA) for yeasts and molds

Tryptic Soy Agar (TSA) for general product testing

For Sterility Testing

Rapid Sterility Media (RSM)

Rapid Micro Biosystems

Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.

Growth Direct® modernizes MQC

M A N U A L W O R K F L O W

1 .

P U L L Q C

TE S T F O R M

2 .

F IL L O U T

A S S A Y IN F O

3 .

P R E P A R E S A MP L E S

4 .

L O A D

IN C U B A TO R

5 .

P U L L

S A MP L E S

6 .

P E R F O R M C O U N TS

7 .

R E C O R D C O U N TS

8 .

R E TU R N

S A MP L E S

9 .

S H IF T

S A MP L E S

10 .

P U L L

S A MP L E S

11 .

P E R F O R M C O U N TS

12 .

P E R F O R M

D U A L - R E A D

13 .

R E C O R D C O U N TS

14 .

K E Y

IN TO L IM S

15 .

D IS C A R D

R E S U L TS

G R O W T H D I R E C T ® A U T O M A T E D W O R K F L O W

Manual & subject to error 15 steps

5-14 days to result / test Unsecured

Automated & accurate 2 steps

Results in half the time Full data integrity

Rapid Micro Biosystems

Prepare sample & Automated incubation and

1 automated loading 2 analysis & data handling

The Growth Direct® System brings MQC into the 21st Century

F A C T O R S D R I V I N G C H A N G E

Scientific and +

technology innovation

Growing demand for

more complex therapies

Faster & leaner

manufacturing

Data integrity &

security focus

Regulatory

scrutiny

T O D A Y

Discovery & research

High-throughput R&D automation

T O D A Y

QC & Analysis

Bioprocessing & manufacturing

Flexible single use technologies

Large and growing TAM for pharma MQC testing

Our core pharma market is

significant with strong fundamental growth

~430M

Tests Annually

Recurring Annual TAM

~10,000

Growth Direct

Systems Globally

One-time TAM

Pharma MQC Market Growth

CAGR 2026 - 2034

Total Market

7%+

Biologics (excl. C&GT)

30%+

Cell & Gene Therapies

Rapid Micro Biosystems

Sources: HealthAdvances Study, IMMR-6 Report, RMB analysis 12

Broad initial traction in Top 20 pharma provides compelling expansion opportunity

Illustrative pharma customer ordering cadence

Core Pharma Market

~10,000 systems

Top 20 Pharma Market

~6,000 systems

Current Top 20 Customers

(15 of Top 20) Potential Market

~4,000 - 5,000 systems

Initial Order

1 to 3 Systems

Multi-Phase Follow-on Orders

Up to 15+ Systems per phase

Years 1-2

Years 3-5+

3 of current Top 20 customers (2) 12 of current Top 20 customers (2)

Drivers of customer order size and timing

Enterprise and site-based budget and priorities

Site readiness (construction / renovation / expansion)

Site-based resource availability

Complexity of global capital purchasing processes

Current Top 20 Customers

(15 of Top 20)

~110 systems placed (1)

Subset of 190 cumulative systems placed across all customers as of December 31, 2025.

As of December 31, 2025.

Rapid Micro Biosystems

Sources: HealthAdvances Study, RMB analysis 13

Market forces pushing pharma industry to automation

Large and Growing Market

$5B annual recurring revenue + $5B global system opportunity

Regulatory Pressure

Increasing regulatory scrutiny and enforcement around data integrity and quality

Industry Change

Growth in complex biologics and cell & gene therapies which require faster, more accurate, higher throughput testing capabilities

Expanding Manufacturing Capacity, Especially

U.S. Reshoring

Increasing investments in new manufacturing capacity create significant opportunity for automation

Rapid Micro Biosystems

Sources: FDA, EvaluatePharma, Alliance for Regen. Medicine 14

Land and expand growth strategy augmented by innovation

G R O W N EW

C U ST O M ER AD O P T I O N

D R I V E EN T ER P RI S E

D EP L O Y M EN T S

B IO

PH A RMA

( in c l . c e l l & g e n e )

Site

1 EM + W/BB + Sterility

CD MO

Site

2 EM + W/BB + Sterility

STERILE

IN JEC TA B LE, V A CC IN E,

& O TH ER

Site

3+ EM + W/BB + Sterility

LAND AND EXPAND ST RAT EGY

EX P A N D I N T O

N EW G EO G R AP H I ES

LA U N C H N EW P R O D U C T S

AN D SE R V I C ES

Sample automation

Additional test types

(e.g. sterility)

Automated microbial ID

AI & cloud-driven data services

Core Growth Direct Capabilities

P U R SU E A D JA C EN T M A R K E T S

Customer base includes 75% of the top 20 global pharma companies1 with significant growth potential

G RO W T H D I REC T APP LI C A T I O N S

Environmental

Monitoring

Water

Testing

Bioburden

Testing

Rapid Sterility

Testing

C U S T O M E R S E G M E N T S W I T H E S T A B L I S H E D U S E

Biologics

Cell & Gene Therapy / CAR-T

G L O B A L S I T E S W I T H G R O W T H D I R E C T S Y S T E M S

CDMO

Personal Care Products Small Molecules

190

cumulative systems placed

75%

of top 20 global pharma are customers

86%

of approved CAR-T manufacturers have GD system placed

155

cumulative systems validated

~9M

cumulative consumables sold

100+

customer manufacturing sites

Rapid Micro Biosystems 16

Rapid Micro Biosystems

1 By revenue

Strategic opportunity to own the QC & Analysis workflow

CLINICAL /

DIAGNOSTIC

BIOPROCESSING / MANUFACTURING

PROCESS

DEVELOPMENT

DISCOVERY & RESEARCH

W O R K F L OW ( P R E P TO A N A L YS IS )

Widespread adoption of automation, high degree of organized competition

Establishing the new standard in QC & Analysis

Widespread adoption of automation, high degree of organized competition

Rapid Micro Biosystems

Biosystems, Inc. 17

Rapid Micro Biosystems

Advances and accelerates top strategic priorities

Accelerating Growth Direct system placements Expanding gross margins

Driving innovation

Rapid Micro Biosystems

1 The Life Science business of Merck KGaA, Darmstadt, Germany, operating in the U.S. as MilliporeSigma

Global, 5-year, co-exclusive right to sell Growth Direct systems & consumables

Minimum commitment for Growth Direct system purchases in each of the first two years

Leverage MilliporeSigma's extensive salesforce to deepen penetration in core pharma market worldwide

Access to segments beyond pharma including personal care, medical device, cosmetics and food & beverage

Collaboration on Supply Agreement to drive efficiencies, reduce product costs & accelerate gross margin expansion

Collaboration on Joint Product / Technology Innovation

Partnership Highlights

Distribution & Collaboration Partnership with Merck KGaA1 (MilliporeSigma)

Delivering consistent 20%+ revenue growth

RE V EN U E

Recurring

Non-recurring

$37 - $41M (1)

$17M

2022

2023

2024

2025

2026e

2027e

2028e

2029e

2030e

Potential Revenue Growth Drivers

Scale existing Top 20 pharma customers through site and application expansion

Win new Top 20 and core pharma customers

Expand new products / services

Meaningful MilliporeSigma contribution across core and adjacent markets beginning in 2026

Leverage global automation standardization

Capture U.S. reshoring & capacity build-out

2026 revenue guidance range issued on March 12, 2026

Note: Data for 2026 - 2030 represents estimated future revenue based on current expectations, actual results may differ

Rapid Micro Biosystems

Diverse drivers of potential significant gross margin expansion

Systems

Direct material cost reduction

Increased manufacturing efficiencies

Expansion of outsourcing

Consumables (1)

Direct material cost reduction

Increased automation line throughput and other manufacturing efficiencies

Automation of manual work

Conversion of variable costs to scalable fixed costs (e.g., packaging)

Potential for outsourced

Overhead (1)

(Systems & Consumables)

Current cost structure reflects major upfront investments

This provides significant future capacity with minimal incremental investment

Significant cost leverage is expected to continue to drive outsized gross margin expansion

Services (1)

Significant leverage as service revenue and installed base grow faster than headcount needs

Reductions in time / cost to validate and service customer systems

2029 - 2030

Gross Margin Targets

50%+ (2)

manufacturing over time

60%+ (2)

50 - 60%+ (2)

Rapid Micro Biosystems

Area includes gross margin expansion opportunities related to MilliporeSigma partnership

Represents 2029 - 2030 gross margin targets; actual results may differ 20

Significant progress and clear path to potential 50%+ gross margin

G RO SS M AR G I N %

50%

56 percentage point

improvement (actual)

(50%)

2022 Actual

2025 Actual

2026 Guidance

2028 Goal

(50%)

6% (1)

~20%

50%+

(exit)

Systems Consumables Service

Contribution to overall improvement

Expected primary drivers of 2026 Improvement

Systems: Material cost reduction, volume leverage

Consumables: Material cost reduction, volume leverage

Service: Higher productivity and lower per-unit service costs

Note: Data for 2026 - 2028 represents estimated future gross margin percentage based on current expectations, actual results may differ

2025 Gross Margin is adjusted to remove the impact of the one-time inventory write-down recorded in Q4 2025. See Rapid Micro

Rapid Micro Biosystems

trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.

Biosystems earnings release dated March 12, 2026 for reconciliation of total gross margin to Non-GAAP adjusted total gross margin. 21

2026 Gross Margin guidance issued on March 12, 2026.

Disclaimer

Rapid Micro Biosystems Inc. published this content on May 14, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 13, 2026 at 21:00 UTC.